Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABARESC: Budesonide effect on cabazitaxel-induced diarrhea in mCRPC
2011-003346-40Phase 2Completed
- Sponsor
- Erasmus MC Cancer Institute
- Start
- Aug 2011
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) comparing Cabazitaxel alone with Cabazitaxel plus budesonide (2 arms). Primary endpoint: Incidence of cabazitaxel-induced diarrhea. Started Aug 2011; status: completed.
02
Drugs
cabazitaxelbudesonide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2011-003346-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003346-40.